Keros Therapeutics, Inc. (KROS)
19.52
+0.64
(+3.39%)
USD |
NASDAQ |
Jan 13, 16:00
19.52
0.00 (0.00%)
After-Hours: 20:00
Keros Therapeutics Research and Development Expense (Annual): 173.63M for Dec. 31, 2024
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Eli Lilly & Co. | 10.99B |
| Pfizer Inc. | 10.74B |
| Innoviva, Inc. | 13.65M |
| Ocugen, Inc. | 30.16M |
| Bionano Genomics, Inc. | 24.80M |